CRVO | CervoMed Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.36 - 9.69
52 Week Range	1.8000 - 25.92
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,049,248
Average Volume	4,696,303
Shares Outstanding	8,702,720
Market Cap	82,501,786
Sector	Healthcare
Industry	Biotechnology
IPO Date	2008-05-23

Valuation
Profitability
Growth
Health
P/E Ratio	-4.69
Forward P/E Ratio	N/A
EPS	-2.02
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	CRVO

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

*Chart delayed

Analyzing fundamentals for CRVO we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CRVO Fundamentals page.

Watching at CRVO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CRVO Technicals page.